BindingDB logo
myBDB logout

Patent code US10781181

Compile Data Set for Download or QSAR

Found 216 hits of Enzyme Inhibition Constant Data   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kJ/mole
IC50
nM
Kd
nM
EC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Plasma kallikrein


(Homo sapiens (Human))
BDBM463332
PNG
(3-Amino-1-[(4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl...)
Show SMILES Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCCOc1cccc(Cl)c1
Show InChI InChI=1S/C25H24ClN5O3/c26-20-4-3-5-21(14-20)34-13-11-28-25(33)22-17-31(29-24(22)27)16-19-9-7-18(8-10-19)15-30-12-2-1-6-23(30)32/h1-10,12,14,17H,11,13,15-16H2,(H2,27,29)(H,28,33)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 2.90n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463360
PNG
(3-amino-N-[3-(3-chlorophenyl)propyl]-1-({4-[(2-oxo...)
Show SMILES Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCCCc1cccc(Cl)c1
Show InChI InChI=1S/C26H26ClN5O2/c27-22-7-3-5-19(15-22)6-4-13-29-26(34)23-18-32(30-25(23)28)17-21-11-9-20(10-12-21)16-31-14-2-1-8-24(31)33/h1-3,5,7-12,14-15,18H,4,6,13,16-17H2,(H2,28,30)(H,29,34)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 3.20n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463407
PNG
(3-amino-N-[2-(3-chlorophenoxy)ethyl]-1-({4-[(3-met...)
Show SMILES Cc1cccn(Cc2ccc(Cn3cc(C(=O)NCCOc4cccc(Cl)c4)c(N)n3)cc2)c1=O
Show InChI InChI=1S/C26H26ClN5O3/c1-18-4-3-12-31(26(18)34)15-19-7-9-20(10-8-19)16-32-17-23(24(28)30-32)25(33)29-11-13-35-22-6-2-5-21(27)14-22/h2-10,12,14,17H,11,13,15-16H2,1H3,(H2,28,30)(H,29,33)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 3.5n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463429
PNG
(3-amino-N-[(3S)-1-(3-chlorophenyl)pyrrolidin-3-yl]...)
Show SMILES Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)N[C@H]1CCN(C1)c1cccc(Cl)c1
Show InChI InChI=1S/C27H27ClN6O2/c28-21-4-3-5-23(14-21)32-13-11-22(17-32)30-27(36)24-18-34(31-26(24)29)16-20-9-7-19(8-10-20)15-33-12-2-1-6-25(33)35/h1-10,12,14,18,22H,11,13,15-17H2,(H2,29,31)(H,30,36)/t22-/m0/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 3.80n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463434
PNG
(3-amino-N-[(3R)-1-(3-chlorophenyl)-2-oxopyrrolidin...)
Show SMILES Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)N[C@@H]1CCN(C1=O)c1cccc(Cl)c1
Show InChI InChI=1S/C27H25ClN6O3/c28-20-4-3-5-21(14-20)34-13-11-23(27(34)37)30-26(36)22-17-33(31-25(22)29)16-19-9-7-18(8-10-19)15-32-12-2-1-6-24(32)35/h1-10,12,14,17,23H,11,13,15-16H2,(H2,29,31)(H,30,36)/t23-/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 4n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463431
PNG
(3-amino-N-[(3S)-1-(3-chlorophenyl)-2-oxopyrrolidin...)
Show SMILES Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)N[C@H]1CCN(C1=O)c1cccc(Cl)c1
Show InChI InChI=1S/C27H25ClN6O3/c28-20-4-3-5-21(14-20)34-13-11-23(27(34)37)30-26(36)22-17-33(31-25(22)29)16-19-9-7-18(8-10-19)15-32-12-2-1-6-24(32)35/h1-10,12,14,17,23H,11,13,15-16H2,(H2,29,31)(H,30,36)/t23-/m0/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 4.80n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463334
PNG
(3-Amino-N-[(2S)-2-(3-chlorophenoxy)propyl]-1-({4-[...)
Show SMILES C[C@@H](CNC(=O)c1cn(Cc2ccc(Cn3ccccc3=O)cc2)nc1N)Oc1cccc(Cl)c1
Show InChI InChI=1S/C26H26ClN5O3/c1-18(35-22-6-4-5-21(27)13-22)14-29-26(34)23-17-32(30-25(23)28)16-20-10-8-19(9-11-20)15-31-12-3-2-7-24(31)33/h2-13,17-18H,14-16H2,1H3,(H2,28,30)(H,29,34)/t18-/m0/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 5.60n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463355
PNG
(N-[2-(3-chlorophenoxy)ethyl]-1-({4-[(2-oxopyridin-...)
Show SMILES Clc1cccc(OCCNC(=O)c2cnn(Cc3ccc(Cn4ccccc4=O)cc3)c2)c1
Show InChI InChI=1S/C25H23ClN4O3/c26-22-4-3-5-23(14-22)33-13-11-27-25(32)21-15-28-30(18-21)17-20-9-7-19(8-10-20)16-29-12-2-1-6-24(29)31/h1-10,12,14-15,18H,11,13,16-17H2,(H,27,32)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 6.10n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463423
PNG
(3-amino-N-[2-(3-chlorophenoxy)ethyl]-1-({4-[(5-flu...)
Show SMILES Nc1nn(Cc2ccc(Cn3cc(F)ccc3=O)cc2)cc1C(=O)NCCOc1cccc(Cl)c1
Show InChI InChI=1S/C25H23ClFN5O3/c26-19-2-1-3-21(12-19)35-11-10-29-25(34)22-16-32(30-24(22)28)14-18-6-4-17(5-7-18)13-31-15-20(27)8-9-23(31)33/h1-9,12,15-16H,10-11,13-14H2,(H2,28,30)(H,29,34)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 6.20n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463356
PNG
(N-[2-(3-chlorophenoxy)ethyl]-3-cyano-1-({4-[(2-oxo...)
Show SMILES Clc1cccc(OCCNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2C#N)c1
Show InChI InChI=1S/C26H22ClN5O3/c27-21-4-3-5-22(14-21)35-13-11-29-26(34)23-18-32(30-24(23)15-28)17-20-9-7-19(8-10-20)16-31-12-2-1-6-25(31)33/h1-10,12,14,18H,11,13,16-17H2,(H,29,34)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 6.5n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463424
PNG
(3-amino-N-[2-(3-chlorophenoxy)ethyl]-1-({2-fluoro-...)
Show SMILES Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2F)cc1C(=O)NCCOc1cccc(Cl)c1
Show InChI InChI=1S/C25H23ClFN5O3/c26-19-4-3-5-20(13-19)35-11-9-29-25(34)21-16-32(30-24(21)28)15-18-8-7-17(12-22(18)27)14-31-10-2-1-6-23(31)33/h1-8,10,12-13,16H,9,11,14-15H2,(H2,28,30)(H,29,34)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 7.60n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463421
PNG
(3-amino-N-[2-(3-chlorophenoxy)ethyl]-1-({3-methoxy...)
Show SMILES COc1cc(Cn2cc(C(=O)NCCOc3cccc(Cl)c3)c(N)n2)ccc1Cn1ccccc1=O
Show InChI InChI=1S/C26H26ClN5O4/c1-35-23-13-18(8-9-19(23)16-31-11-3-2-7-24(31)33)15-32-17-22(25(28)30-32)26(34)29-10-12-36-21-6-4-5-20(27)14-21/h2-9,11,13-14,17H,10,12,15-16H2,1H3,(H2,28,30)(H,29,34)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 9.40n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463351
PNG
(3-amino-N-[2-(5-chloro-2-cyanophenoxy)ethyl]-1-({4...)
Show SMILES Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCCOc1cc(Cl)ccc1C#N
Show InChI InChI=1S/C26H23ClN6O3/c27-21-9-8-20(14-28)23(13-21)36-12-10-30-26(35)22-17-33(31-25(22)29)16-19-6-4-18(5-7-19)15-32-11-2-1-3-24(32)34/h1-9,11,13,17H,10,12,15-16H2,(H2,29,31)(H,30,35)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 10.1n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463358
PNG
(2-{[3-amino-1-({4-[(2-oxopyridin-1-yl)methyl]pheny...)
Show SMILES CN(C(=O)CNC(=O)c1cn(Cc2ccc(Cn3ccccc3=O)cc2)nc1N)c1cccc(Cl)c1
Show InChI InChI=1S/C26H25ClN6O3/c1-31(21-6-4-5-20(27)13-21)24(35)14-29-26(36)22-17-33(30-25(22)28)16-19-10-8-18(9-11-19)15-32-12-3-2-7-23(32)34/h2-13,17H,14-16H2,1H3,(H2,28,30)(H,29,36)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 12.6n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463441
PNG
(3-amino-N-[(2R/S)-2-(3-chlorophenoxy)propyl]-1-({4...)
Show SMILES C[C@@H](CNC(=O)c1cn(Cc2ccc(Cn3ccccc3=O)cc2)nc1N)Oc1cccc(Cl)c1
Show InChI InChI=1S/C26H26ClN5O3/c1-18(35-22-6-4-5-21(27)13-22)14-29-26(34)23-17-32(30-25(23)28)16-20-10-8-19(9-11-20)15-31-12-3-2-7-24(31)33/h2-13,17-18H,14-16H2,1H3,(H2,28,30)(H,29,34)/t18-/m0/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 13.3n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463357
PNG
(N-[2-(3-chlorophenoxy)ethyl]-3-methyl-1-({4-[(2-ox...)
Show SMILES Cc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCCOc1cccc(Cl)c1
Show InChI InChI=1S/C26H25ClN4O3/c1-19-24(26(33)28-12-14-34-23-6-4-5-22(27)15-23)18-31(29-19)17-21-10-8-20(9-11-21)16-30-13-3-2-7-25(30)32/h2-11,13,15,18H,12,14,16-17H2,1H3,(H,28,33)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 16.3n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463340
PNG
(N-[2-(3-chlorophenoxy)ethyl]-3-(methoxymethyl)-1-(...)
Show SMILES COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCCOc1cccc(Cl)c1
Show InChI InChI=1S/C27H27ClN4O4/c1-35-19-25-24(27(34)29-12-14-36-23-6-4-5-22(28)15-23)18-32(30-25)17-21-10-8-20(9-11-21)16-31-13-3-2-7-26(31)33/h2-11,13,15,18H,12,14,16-17,19H2,1H3,(H,29,34)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 16.6n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463335
PNG
(N-[2-(3-Chlorophenoxy)ethyl]-3-(methylamino)-1-({4...)
Show SMILES CNc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCCOc1cccc(Cl)c1
Show InChI InChI=1S/C26H26ClN5O3/c1-28-25-23(26(34)29-12-14-35-22-6-4-5-21(27)15-22)18-32(30-25)17-20-10-8-19(9-11-20)16-31-13-3-2-7-24(31)33/h2-11,13,15,18H,12,14,16-17H2,1H3,(H,28,30)(H,29,34)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 18.5n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463347
PNG
(3-amlno-N-[2-(3-chloro-4-methylphenoxy)ethyl]-1-({...)
Show SMILES Cc1ccc(OCCNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2N)cc1Cl
Show InChI InChI=1S/C26H26ClN5O3/c1-18-5-10-21(14-23(18)27)35-13-11-29-26(34)22-17-32(30-25(22)28)16-20-8-6-19(7-9-20)15-31-12-3-2-4-24(31)33/h2-10,12,14,17H,11,13,15-16H2,1H3,(H2,28,30)(H,29,34)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 24.6n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463368
PNG
(3-amino-N-{2-[(4-chloropyridin-2-yl)amino]ethyl}-1...)
Show SMILES Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCCNc1cc(Cl)ccn1
Show InChI InChI=1S/C24H24ClN7O2/c25-19-8-9-27-21(13-19)28-10-11-29-24(34)20-16-32(30-23(20)26)15-18-6-4-17(5-7-18)14-31-12-2-1-3-22(31)33/h1-9,12-13,16H,10-11,14-15H2,(H2,26,30)(H,27,28)(H,29,34)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 30.1n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463408
PNG
(3-amino-N-[2-(3-chlorophenoxy)ethyl]-1-({4-[(2-oxo...)
Show SMILES Nc1nn(Cc2ccc(Cn3cccnc3=O)cc2)cc1C(=O)NCCOc1cccc(Cl)c1
Show InChI InChI=1S/C24H23ClN6O3/c25-19-3-1-4-20(13-19)34-12-10-27-23(32)21-16-31(29-22(21)26)15-18-7-5-17(6-8-18)14-30-11-2-9-28-24(30)33/h1-9,11,13,16H,10,12,14-15H2,(H2,26,29)(H,27,32)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 30.2n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463435
PNG
(3-amino-N-[(3S)-1-(3-chlorophenyl)-5-oxopyrrolidin...)
Show SMILES Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)N[C@@H]1CN(C(=O)C1)c1cccc(Cl)c1
Show InChI InChI=1S/C27H25ClN6O3/c28-20-4-3-5-22(12-20)34-16-21(13-25(34)36)30-27(37)23-17-33(31-26(23)29)15-19-9-7-18(8-10-19)14-32-11-2-1-6-24(32)35/h1-12,17,21H,13-16H2,(H2,29,31)(H,30,37)/t21-/m0/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 42.1n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463333
PNG
(3-Amino-1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]...)
Show SMILES Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCC(=O)Nc1cccc(Cl)c1
Show InChI InChI=1S/C25H23ClN6O3/c26-19-4-3-5-20(12-19)29-22(33)13-28-25(35)21-16-32(30-24(21)27)15-18-9-7-17(8-10-18)14-31-11-2-1-6-23(31)34/h1-12,16H,13-15H2,(H2,27,30)(H,28,35)(H,29,33)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 60.2n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463338
PNG
(N-[2-(3-chlorophenoxy)ethyl]-3-cyclopropyl-1-({4-[...)
Show SMILES Clc1cccc(OCCNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2C2CC2)c1
Show InChI InChI=1S/C28H27ClN4O3/c29-23-4-3-5-24(16-23)36-15-13-30-28(35)25-19-33(31-27(25)22-11-12-22)18-21-9-7-20(8-10-21)17-32-14-2-1-6-26(32)34/h1-10,14,16,19,22H,11-13,15,17-18H2,(H,30,35)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 68.4n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463425
PNG
(3-amino-N-[2-(3-chlorophenoxy)ethyl]-1-({5-[(2-oxo...)
Show SMILES Nc1nn(Cc2ccc(Cn3ccccc3=O)cn2)cc1C(=O)NCCOc1cccc(Cl)c1
Show InChI InChI=1S/C24H23ClN6O3/c25-18-4-3-5-20(12-18)34-11-9-27-24(33)21-16-31(29-23(21)26)15-19-8-7-17(13-28-19)14-30-10-2-1-6-22(30)32/h1-8,10,12-13,16H,9,11,14-15H2,(H2,26,29)(H,27,33)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 72.1n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463361
PNG
(N-[2-(3-chlorophenoxy)ethyl]-2-methyl-1-({4-[(2-ox...)
Show SMILES Cc1nc(cn1Cc1ccc(Cn2ccccc2=O)cc1)C(=O)NCCOc1cccc(Cl)c1
Show InChI InChI=1S/C26H25ClN4O3/c1-19-29-24(26(33)28-12-14-34-23-6-4-5-22(27)15-23)18-31(19)17-21-10-8-20(9-11-21)16-30-13-3-2-7-25(30)32/h2-11,13,15,18H,12,14,16-17H2,1H3,(H,28,33)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 77n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463353
PNG
(3-amino-N-[2-(2,5-dichlorophenoxy)ethyl]-1-({4-[(2...)
Show SMILES Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCCOc1cc(Cl)ccc1Cl
Show InChI InChI=1S/C25H23Cl2N5O3/c26-19-8-9-21(27)22(13-19)35-12-10-29-25(34)20-16-32(30-24(20)28)15-18-6-4-17(5-7-18)14-31-11-2-1-3-23(31)33/h1-9,11,13,16H,10,12,14-15H2,(H2,28,30)(H,29,34)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 92.8n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463362
PNG
(5-amino-N-[2-(3-chlorophenoxy)ethyl]-1-({4-[(2-oxo...)
Show SMILES Nc1c(cnn1Cc1ccc(Cn2ccccc2=O)cc1)C(=O)NCCOc1cccc(Cl)c1
Show InChI InChI=1S/C25H24ClN5O3/c26-20-4-3-5-21(14-20)34-13-11-28-25(33)22-15-29-31(24(22)27)17-19-9-7-18(8-10-19)16-30-12-2-1-6-23(30)32/h1-10,12,14-15H,11,13,16-17,27H2,(H,28,33)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 96n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463349
PNG
(3-amino-N-[2-(3,4-dichlorophenoxy}ethyl]-1-({4-[(2...)
Show SMILES Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCCOc1ccc(Cl)c(Cl)c1
Show InChI InChI=1S/C25H23Cl2N5O3/c26-21-9-8-19(13-22(21)27)35-12-10-29-25(34)20-16-32(30-24(20)28)15-18-6-4-17(5-7-18)14-31-11-2-1-3-23(31)33/h1-9,11,13,16H,10,12,14-15H2,(H2,28,30)(H,29,34)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 96.8n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463399
PNG
(3-amino-N-[2-(3-chlorophenoxy)ethyl]-1-({4-[(2-oxo...)
Show SMILES Nc1nn(Cc2ccc(CN3CCCCC3=O)cc2)cc1C(=O)NCCOc1cccc(Cl)c1
Show InChI InChI=1S/C25H28ClN5O3/c26-20-4-3-5-21(14-20)34-13-11-28-25(33)22-17-31(29-24(22)27)16-19-9-7-18(8-10-19)15-30-12-2-1-6-23(30)32/h3-5,7-10,14,17H,1-2,6,11-13,15-16H2,(H2,27,29)(H,28,33)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 112n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463352
PNG
(3-amino-N-[2-(3-chloro-5-methylphenoxy)ethyl]-1-({...)
Show SMILES Cc1cc(Cl)cc(OCCNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2N)c1
Show InChI InChI=1S/C26H26ClN5O3/c1-18-12-21(27)14-22(13-18)35-11-9-29-26(34)23-17-32(30-25(23)28)16-20-7-5-19(6-8-20)15-31-10-3-2-4-24(31)33/h2-8,10,12-14,17H,9,11,15-16H2,1H3,(H2,28,30)(H,29,34)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 114n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463354
PNG
(N-[2-(3-chlorophenoxy)ethyl]-3-(dimethylamino)-1-(...)
Show SMILES CN(C)c1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCCOc1cccc(Cl)c1
Show InChI InChI=1S/C27H28ClN5O3/c1-31(2)26-24(27(35)29-13-15-36-23-7-5-6-22(28)16-23)19-33(30-26)18-21-11-9-20(10-12-21)17-32-14-4-3-8-25(32)34/h3-12,14,16,19H,13,15,17-18H2,1-2H3,(H,29,35)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 122n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463342
PNG
(N-[2-(3-chloro-5-fluorophenoxy)ethyl]-3-(methoxyme...)
Show SMILES COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCCOc1cc(F)cc(Cl)c1
Show InChI InChI=1S/C27H26ClFN4O4/c1-36-18-25-24(27(35)30-9-11-37-23-13-21(28)12-22(29)14-23)17-33(31-25)16-20-7-5-19(6-8-20)15-32-10-3-2-4-26(32)34/h2-8,10,12-14,17H,9,11,15-16,18H2,1H3,(H,30,35)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 134n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463438
PNG
(3-amino-N-[(2S)-1-(3-chlorophenoxy)propan-2-yl]-1-...)
Show SMILES C[C@@H](COc1cccc(Cl)c1)NC(=O)c1cn(Cc2ccc(Cn3ccccc3=O)cc2)nc1N
Show InChI InChI=1S/C26H26ClN5O3/c1-18(17-35-22-6-4-5-21(27)13-22)29-26(34)23-16-32(30-25(23)28)15-20-10-8-19(9-11-20)14-31-12-3-2-7-24(31)33/h2-13,16,18H,14-15,17H2,1H3,(H2,28,30)(H,29,34)/t18-/m0/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 140n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463346
PNG
(3-amino-N-[2-(5-chloro-2-methylphenoxy)ethyl]-1-({...)
Show SMILES Cc1ccc(Cl)cc1OCCNC(=O)c1cn(Cc2ccc(Cn3ccccc3=O)cc2)nc1N
Show InChI InChI=1S/C26H26ClN5O3/c1-18-5-10-21(27)14-23(18)35-13-11-29-26(34)22-17-32(30-25(22)28)16-20-8-6-19(7-9-20)15-31-12-3-2-4-24(31)33/h2-10,12,14,17H,11,13,15-16H2,1H3,(H2,28,30)(H,29,34)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 161n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463341
PNG
(N-[2-(5-chloro-2-fluorophenoxy)ethyl]-3-(methoxyme...)
Show SMILES COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCCOc1cc(Cl)ccc1F
Show InChI InChI=1S/C27H26ClFN4O4/c1-36-18-24-22(27(35)30-11-13-37-25-14-21(28)9-10-23(25)29)17-33(31-24)16-20-7-5-19(6-8-20)15-32-12-3-2-4-26(32)34/h2-10,12,14,17H,11,13,15-16,18H2,1H3,(H,30,35)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 191n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463398
PNG
(3-amino-N-[2-(3-chlorophenoxy)ethyl]-1-({4-[(3-oxo...)
Show SMILES Nc1nn(Cc2ccc(CN3CCOCC3=O)cc2)cc1C(=O)NCCOc1cccc(Cl)c1
Show InChI InChI=1S/C24H26ClN5O4/c25-19-2-1-3-20(12-19)34-10-8-27-24(32)21-15-30(28-23(21)26)14-18-6-4-17(5-7-18)13-29-9-11-33-16-22(29)31/h1-7,12,15H,8-11,13-14,16H2,(H2,26,28)(H,27,32)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 227n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463369
PNG
(N-[2-(3-chlorophenoxy)ethyl]-3-(methoxymethyl)-1-(...)
Show SMILES COCc1nn(Cc2ccc(Cn3cc(C)cn3)cc2)cc1C(=O)NCCOc1cccc(Cl)c1
Show InChI InChI=1S/C26H28ClN5O3/c1-19-13-29-31(14-19)15-20-6-8-21(9-7-20)16-32-17-24(25(30-32)18-34-2)26(33)28-10-11-35-23-5-3-4-22(27)12-23/h3-9,12-14,17H,10-11,15-16,18H2,1-2H3,(H,28,33)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 231n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463376
PNG
(3-amino-N-[2-(3-chlorophenoxy)ethyl]-1-[(2-methylq...)
Show SMILES Cc1ccc2cc(Cn3cc(C(=O)NCCOc4cccc(Cl)c4)c(N)n3)ccc2n1
Show InChI InChI=1S/C23H22ClN5O2/c1-15-5-7-17-11-16(6-8-21(17)27-15)13-29-14-20(22(25)28-29)23(30)26-9-10-31-19-4-2-3-18(24)12-19/h2-8,11-12,14H,9-10,13H2,1H3,(H2,25,28)(H,26,30)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 245n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463359
PNG
(3-amino-N-{2-[(3-chlorophenyl)(methyl)amino]ethyl}...)
Show SMILES CN(CCNC(=O)c1cn(Cc2ccc(Cn3ccccc3=O)cc2)nc1N)c1cccc(Cl)c1
Show InChI InChI=1S/C26H27ClN6O2/c1-31(22-6-4-5-21(27)15-22)14-12-29-26(35)23-18-33(30-25(23)28)17-20-10-8-19(9-11-20)16-32-13-3-2-7-24(32)34/h2-11,13,15,18H,12,14,16-17H2,1H3,(H2,28,30)(H,29,35)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 264n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463344
PNG
(N-[2-(3-chloro-4-fluorophenoxy)ethyl]-3-(methoxyme...)
Show SMILES COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCCOc1ccc(F)c(Cl)c1
Show InChI InChI=1S/C27H26ClFN4O4/c1-36-18-25-22(27(35)30-11-13-37-21-9-10-24(29)23(28)14-21)17-33(31-25)16-20-7-5-19(6-8-20)15-32-12-3-2-4-26(32)34/h2-10,12,14,17H,11,13,15-16,18H2,1H3,(H,30,35)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 266n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463405
PNG
(3-amino-N-[2-(3-chlorophenoxy)ethyl]-1-[(4- | US10...)
Show SMILES CN(C)C(=O)N(C)Cc1ccc(Cn2cc(C(=O)NCCOc3cccc(Cl)c3)c(N)n2)cc1
Show InChI InChI=1S/C24H29ClN6O3/c1-29(2)24(33)30(3)14-17-7-9-18(10-8-17)15-31-16-21(22(26)28-31)23(32)27-11-12-34-20-6-4-5-19(25)13-20/h4-10,13,16H,11-12,14-15H2,1-3H3,(H2,26,28)(H,27,32)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 298n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463432
PNG
(3-amino-N-[(3R)-1-[(3-chlorophenyl)methyl]pyrrolid...)
Show SMILES Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)N[C@@H]1CCN(Cc2cccc(Cl)c2)C1
Show InChI InChI=1S/C28H29ClN6O2/c29-23-5-3-4-22(14-23)15-33-13-11-24(18-33)31-28(37)25-19-35(32-27(25)30)17-21-9-7-20(8-10-21)16-34-12-2-1-6-26(34)36/h1-10,12,14,19,24H,11,13,15-18H2,(H2,30,32)(H,31,37)/t24-/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 299n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463437
PNG
(3-amino-N-[(2R)-1-(3-chlorophenoxy)propan-2-yl]-1-...)
Show SMILES C[C@H](COc1cccc(Cl)c1)NC(=O)c1cn(Cc2ccc(Cn3ccccc3=O)cc2)nc1N
Show InChI InChI=1S/C26H26ClN5O3/c1-18(17-35-22-6-4-5-21(27)13-22)29-26(34)23-16-32(30-25(23)28)15-20-10-8-19(9-11-20)14-31-12-3-2-7-24(31)33/h2-13,16,18H,14-15,17H2,1H3,(H2,28,30)(H,29,34)/t18-/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 316n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463372
PNG
(3-amino-N-[2-(3-chlorophenoxy)ethyl]-1-{[2-(pyrrol...)
Show SMILES Nc1nn(Cc2ccnc(c2)N2CCCC2)cc1C(=O)NCCOc1cccc(Cl)c1
Show InChI InChI=1S/C22H25ClN6O2/c23-17-4-3-5-18(13-17)31-11-8-26-22(30)19-15-29(27-21(19)24)14-16-6-7-25-20(12-16)28-9-1-2-10-28/h3-7,12-13,15H,1-2,8-11,14H2,(H2,24,27)(H,26,30)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 326n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463374
PNG
(3-amino-N-[2-(3-chlorophenoxy)ethyl]-1-{[4-(2-oxop...)
Show SMILES Nc1nn(Cc2ccc(cc2)-n2ccccc2=O)cc1C(=O)NCCOc1cccc(Cl)c1
Show InChI InChI=1S/C24H22ClN5O3/c25-18-4-3-5-20(14-18)33-13-11-27-24(32)21-16-29(28-23(21)26)15-17-7-9-19(10-8-17)30-12-2-1-6-22(30)31/h1-10,12,14,16H,11,13,15H2,(H2,26,28)(H,27,32)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 335n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463433
PNG
(3-amino-N-[(3S)-1-[(3-chlorophenyl)methyl]pyrrolid...)
Show SMILES Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)N[C@H]1CCN(Cc2cccc(Cl)c2)C1
Show InChI InChI=1S/C28H29ClN6O2/c29-23-5-3-4-22(14-23)15-33-13-11-24(18-33)31-28(37)25-19-35(32-27(25)30)17-21-9-7-20(8-10-21)16-34-12-2-1-6-26(34)36/h1-10,12,14,19,24H,11,13,15-18H2,(H2,30,32)(H,31,37)/t24-/m0/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 384n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463439
PNG
((2S)-2-{[3-amino-1-({4-[(2-oxopyridin-1-yl)methyl]...)
Show SMILES C[C@H](NC(=O)c1cn(Cc2ccc(Cn3ccccc3=O)cc2)nc1N)C(=O)N(C)c1cccc(Cl)c1
Show InChI InChI=1S/C27H27ClN6O3/c1-18(27(37)32(2)22-7-5-6-21(28)14-22)30-26(36)23-17-34(31-25(23)29)16-20-11-9-19(10-12-20)15-33-13-4-3-8-24(33)35/h3-14,17-18H,15-16H2,1-2H3,(H2,29,31)(H,30,36)/t18-/m0/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 390n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463428
PNG
(N-[2-(3-chlorophenoxy)ethyl]-3-(methoxymethyl)-1-(...)
Show SMILES COCc1nn(Cc2ccc(Cn3ccc(C)cc3=O)cc2)cc1C(=O)NCCOc1cccc(Cl)c1
Show InChI InChI=1S/C28H29ClN4O4/c1-20-10-12-32(27(34)14-20)16-21-6-8-22(9-7-21)17-33-18-25(26(31-33)19-36-2)28(35)30-11-13-37-24-5-3-4-23(29)15-24/h3-10,12,14-15,18H,11,13,16-17,19H2,1-2H3,(H,30,35)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 413n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM463373
PNG
(3-amino-N-[2-(3-chlorophenoxy)ethyl]-1-({4-[(pyrro...)
Show SMILES Nc1nn(Cc2ccc(cc2)C(=O)N2CCCC2)cc1C(=O)NCCOc1cccc(Cl)c1
Show InChI InChI=1S/C24H26ClN5O3/c25-19-4-3-5-20(14-19)33-13-10-27-23(31)21-16-30(28-22(21)26)15-17-6-8-18(9-7-17)24(32)29-11-1-2-12-29/h3-9,14,16H,1-2,10-13,15H2,(H2,26,28)(H,27,31)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 427n/an/an/an/an/an/a



KALVISTA PHARMACEUTICALS LIMITED

US Patent


Assay Description
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...


US Patent US10781181 (2020)

More data for this
Ligand-Target Pair
Displayed 1 to 50 (of 216 total )  |  Next  |  Last  >>
* indicates data uncertainty>20%